Core Insights - Deep-pocketed investors are showing a bullish sentiment towards Boston Scientific, indicating potential significant developments ahead [1] - The options activity for Boston Scientific is unusually high, with 57% of investors leaning bullish and 35% bearish [2] Options Activity - There have been 14 extraordinary options activities for Boston Scientific, with 11 puts totaling $1,052,058 and 3 calls amounting to $556,910 [2] - The predicted price range for Boston Scientific over the last 3 months is between $65.0 and $105.0 [3] Volume and Open Interest - The average open interest for Boston Scientific options is 1,935.45, with total trading volume reaching 11,370.00 [4] - A chart illustrates the trends in call and put option volume and open interest for high-value trades within the $65.0 to $105.0 strike price corridor over the last 30 days [4] Company Performance - The average target price proposed by 5 industry analysts for Boston Scientific is $104.0 [6] - The current trading volume stands at 9,058,332, with the stock price up by 2.43% at $77.33 [7] - The earnings announcement for Boston Scientific is expected in 76 days [7]

Core Insights - Boston Scientific reported revenue of $20 billion for fiscal year 2025, with Q4 2025 revenue reaching $5.2 billion, a 15.9% increase compared to Q4 2024 [1][3] - Despite strong growth, the company's shares fell 11% at market open on February 4, 2026, and further declined by 7.2% by market close on the same day [2] Financial Performance - In Q4 2025, the cardiovascular portfolio generated $3.4 billion in revenue, marking an 18.2% increase from Q4 2024 [3] - For FY25, the cardiovascular segment contributed $13.3 billion, reflecting a growth margin of 23.2% compared to $10.8 billion in FY24 [3] Segment Analysis - The electrophysiology (EP) segment, including the Farapulse system, reported Q4 revenues of $890 million, a year-over-year growth of 37.1%, but flat compared to Q3 2025's $865 million [5] - The Watchman franchise achieved Q4 sales of $535 million, a 29.4% increase from Q4 2024, but only a slight rise from $512 million in Q3 2025 [6] Market Outlook - Boston expects growth in 2026 to be in the range of 10.5% to 11.5%, with earnings projected between $3.43 and $3.49 per share [6] - The company anticipates a 15% growth in the EP market for 2026 [6] Analyst Insights - Analysts expressed concerns regarding flat sales in the EP and Watchman segments, which are critical growth drivers for the company [7] - CEO Mike Mahoney indicated that the market growth in Q4 was likely closer to 18% to 20%, rather than the 25% claimed by other companies [8]

Core Insights - Boston Scientific Corporation reported strong fourth-quarter earnings for 2025, with revenues of $5.29 billion, slightly above the consensus estimate of $5.28 billion and exceeding management guidance of $5.22 billion to $5.31 billion [1] - The company achieved adjusted earnings of 80 cents per share, surpassing the consensus of 78 cents and management guidance of 77 to 79 cents [1] Revenue Forecast - For 2026, Boston Scientific forecasts net sales growth of approximately 10.5% to 11.5% on a reported basis and 10% to 11% organically, with expected sales between $22.18 billion and $22.38 billion, compared to the consensus of $22.37 billion [2] - The company estimates adjusted earnings per share for 2026 to be between $3.43 and $3.49, against the consensus of $3.47 [2] Market Reaction - Following the earnings announcement, Boston Scientific shares increased by 0.6%, reaching $75.92 in pre-market trading [2] - Analysts have adjusted their price targets for Boston Scientific in response to the earnings results [3]

Core Insights - Boston Scientific Corporation reported fourth-quarter results that surpassed revenue and earnings expectations, but weakness in its electrophysiology business negatively impacted investor sentiment, leading to a more than 9% decline in shares during premarket trading [1] Financial Performance - The company reported fourth-quarter revenue of $5.29 billion, slightly above Stifel's estimate of $5.25 billion and the consensus forecast of $5.28 billion, with organic revenue growth for the quarter reaching 15.9% [1] - Earnings per share were reported at $0.80, exceeding Stifel's estimate of $0.77 and the consensus forecast of $0.78, attributed to a lower-than-expected effective tax rate of approximately 9.3% [3] Segment Performance - The electrophysiology segment, which represented roughly 17% of total quarterly revenue, underperformed expectations with segment revenue totaling $890 million, significantly below the consensus estimate of $933 million, primarily due to softer demand in the U.S. market [2] Future Guidance - For 2026, the company guided for organic revenue growth of 10% to 11% and earnings per share in the range of $3.43 to $3.49, with first-quarter organic revenue growth expected to range from 8.5% to 10%, indicating stronger growth anticipated in the latter half of the year [3]

Core Insights - Boston Scientific Corporation (BSX) reported fourth-quarter 2025 adjusted earnings per share (EPS) of 80 cents, a 14.3% increase from the previous year, surpassing the Zacks Consensus Estimate by 2.6% and exceeding the company's guidance of 77-79 cents [1][2] - The company's full-year adjusted EPS reached $3.06, marking a 21.9% increase from 2024, also exceeding the Zacks Consensus Estimate by 0.7% and the 2025 guidance range of $3.02-$3.04 [2] Revenue Performance - Fourth-quarter revenues totaled $5.29 billion, reflecting a 15.9% year-over-year increase on a reported basis and 14.3% on an operational basis, with organic growth of 12.7% [3] - For the full year 2025, revenues were $20.07 billion, up 19.9% on a reported basis, 19.2% operationally, and 15.8% organically compared to 2024 [4] Regional Revenue Breakdown - In Q4, revenues increased by 17% in the United States, 12.4% in Europe, the Middle East and Africa (EMEA), 15.2% in the Asia Pacific, and 15.9% in Latin America and Canada [5] Segment Performance - MedSurg revenues in Q4 were $1.81 billion, up 15.9% year over year, with Endoscopy generating $760 million (8.2% organic growth) and Urology revenues at $717 million (3.2% organic growth) [7] - The Cardiovascular segment generated $3.48 billion in Q4 revenues, an 18.2% increase reported and 16.1% organically year over year [10] Margin Analysis - The gross margin expanded by 172 basis points to 69.6%, while adjusted operating margin increased by 180 basis points to 24% despite rising costs [11] Future Outlook - For 2026, Boston Scientific anticipates net sales growth of approximately 10.5-11.5% on a reported basis and 10-11% organically, with adjusted EPS expected in the range of $3.43-$3.49 [12] - Q1 2026 revenue growth is projected at 10.5-12% on a reported basis and 8.5-10% organically, with adjusted earnings expected between 78-80 cents per share [13] Strategic Developments - The company achieved broad regulatory approvals and clinical milestones across various franchises, including strategic acquisitions to enhance its vascular and neuromodulation portfolio [15]

Core Viewpoint - Boston Scientific's stock is set to experience its largest single-day decline in over 25 years, with a recent drop of 16.9% [1] Group 1 - The company's stock price is facing significant pressure, indicating potential underlying issues or market reactions [1]

Core Viewpoint - Boston Scientific's stock price dropped by 13.4% following the release of its fourth-quarter financial report [1] Group 1 - The company reported its fourth-quarter earnings, which led to a significant decline in stock value [1]

Core Viewpoint - The medical-device maker reported a 16% increase in sales but provided a weak forecast for the year, leading to a decline in shares during premarket trading [1] Group 1 - Sales increased by 16% year-over-year, indicating strong demand for the company's products [1] - The company issued a soft forecast for the upcoming year, which has raised concerns among investors [1] - Following the forecast announcement, shares of the company experienced a drop in premarket trading [1]

Boston Scientific (NYSE:BSX) Q4 2025 Earnings call February 04, 2026 08:00 AM ET Company ParticipantsDavid Roman - Managing DirectorFrederick Wise - Managing DirectorJonathan Monson - CFOKenneth Stein - CMOLauren Tengler - Head of Investor RelationsMichael Mahoney - CEOPatrick Wood - Managing DirectorTravis Steed - Managing DirectorConference Call ParticipantsChris Pasquale with Nephron Research - Partner & Senior AnalystDanielle Antalffy - Senior AnalystJoanne Lynch - AnalystJoshua Jennings - Managing Dire ...

Financial Data and Key Metrics Changes - Fourth quarter consolidated revenue reached $5.286 billion, representing a 15.9% reported growth compared to Q4 2024, with operational revenue growth of 14.3% after excluding a $74 million foreign exchange tailwind [19] - Full year 2025 consolidated revenue was $20.074 billion, marking a 19.9% reported growth versus 2024, with operational revenue growth of 19.2% after excluding a $114 million foreign exchange tailwind [20] - Adjusted EPS for Q4 was $0.80, growing 15% year-over-year, exceeding guidance [19] - Full year 2025 adjusted EPS was $3.06, reflecting a 22% increase compared to 2024, marking the third consecutive year of 20%+ adjusted EPS growth [20] Business Line Data and Key Metrics Changes - Urology sales grew 13% operationally in Q4 and 23% operationally for the full year, but performance was below expectations [5] - Endoscopy achieved 8% organic growth in both Q4 and for the full year, driven by endoluminal surgery and imaging systems [5] - Neuromodulation grew 10% in Q4 and 8% organically for the full year, with strong performance from the brain franchise [6] - Cardiovascular segment delivered 16% operational growth in Q4 and 22% operational growth for the full year [7] - Watchman business grew 29% in Q4 and strong double-digit growth for the full year, driven by concomitant procedures [13] Market Data and Key Metrics Changes - U.S. market grew 17% in Q4 and 26% for the full year, with strong performance in EP, Watchman, and ICTX [3] - Asia Pacific region grew 15% operationally in Q4 and 14% for the full year, led by Japan and China [4] - Europe, Middle East, and Africa grew 5% in Q4 and 3% for the full year, with high single-digit growth excluding Acclarent discontinuation [3] Company Strategy and Development Direction - The company anticipates continued momentum in EP and Watchman, with expectations for higher growth in the second half of 2026 [4] - Strategic acquisitions, including Penumbra and Valencia Technologies, are aimed at entering high-growth segments and expanding product offerings [24][25] - The company is focused on maintaining a strong pipeline of innovative products and expanding its market share in key areas [52][63] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 10%-11% organic revenue growth for 2026, with adjusted EPS growth of 12%-14% [27][28] - The company expects to face challenges in the first half of 2026 due to product discontinuations but anticipates a stronger performance in the second half [46] - Management highlighted the importance of ongoing investments in R&D and strategic M&A to drive future growth [63] Other Important Information - The company expects full-year 2026 adjusted gross margin to be in line with 2025, with a slight expansion in operating margin anticipated [21] - Free cash flow for 2025 was $3.659 billion, exceeding expectations, with a target of approximately $4.2 billion for 2026 [24] Q&A Session Summary Question: Concerns about U.S. EP and Watchman performance - Management noted that U.S. EP grew 35% in Q4, exceeding internal targets, and Watchman grew 29%, indicating strong market performance despite concerns [34][36] Question: Impact of recent trials on Watchman - Management confirmed no negative impact from recent trials on Watchman uptake, with robust growth continuing [41] Question: Expectations for EP growth in 2026 - Management expects EP growth to be around 15%, with confidence in maintaining market leadership despite increased competition [44][51] Question: Diversification of growth drivers - Management emphasized ongoing investments in various business units, including Neuromodulation and Urology, to ensure consistent performance across the portfolio [60][62] Question: Confidence in long-term growth targets - Management reaffirmed confidence in achieving long-term revenue growth targets of 10%+, supported by strategic acquisitions and market leadership [86]